Kyowa Kirin to build new biopharma API building at its Takasaki plant
Japanese drugmaker Kyowa Kirin (TYO: 4151) has decided to build a new active pharmaceutical ingredient (API) manufacturing building (HB7 Building) at its Takasaki plant that is responsible for manufacturing biopharmaceuticals.
The HB7 Building will manufacture APIs for biopharmaceuticals utilizing Kyowa Kirin’s unique antibody technology and protein engineering, and it will be equipped with both a GMP 1 compliant manufacturing facility and pilot facility for investigational APIs in early phase development. Because both facilities are planned to have the same single-use manufacturing equipment, it will be possible to use the same equipment configuration for every step from the initial process development for biopharmaceutical API manufacturing to the manufacturing of the investigational API.
$77 million investment
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze